Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms

PURPOSE: The JAK1/2 inhibitor ruxolitinib has demonstrated significant benefits for patients with Myeloproliferative Neoplasms (MPNs). However, patients often lose response to ruxolitinib or suffer disease progression despite therapy with ruxolitinib. These observations have prompted efforts to devi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Rampal, Raajit K., Pinzon-Ortiz, Maria, Somasundara, Amritha Varshini Hanasoge, Durham, Benjamin, Koche, Richard, Spitzer, Barbara, Mowla, Shoron, Krishnan, Aishwarya, Li, Bing, An, Wenbin, Derkach, Andriy, Devlin, Sean, Rong, Xianhui, Longmire, Tyler, Eisman, Shira Esther, Cordner, Keith, Whitfield, Justin T., Vanasse, Gary, Cao, Alexander, Levine, Ross L.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2021
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8197756/
https://ncbi.nlm.nih.gov/pubmed/33782031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4898
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares